NCT02720510 · OUTCOME

Best Overall Response Rate (ORR) and MRD Negativity After ASCT and Maintenance

A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM) · Source last updated 2018-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Month 3 up to end of study, approximately 3 years.

What was measured

ORR (CR + PR) and MRD negativity after ASCT and maintenance

Analysis population: The study was terminated prematurely and because only 6 patients were enrolled, efficacy data were not evaluated.

Groups in this outcome

Arm 1 - RVD + Pan

Revlimid, Velcade, dexamethasone and Farydak

Arm 2 - RVD

Revlimid, Velcade and Dexamethasone

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Arm 1 - RVD + Pan	0
Arm 2 - RVD	0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denoms

counts
group Id
OG000
value
0
group Id
OG001
value
0
units
Participants

description

ORR (CR + PR) and MRD negativity after ASCT and maintenance

groups

description
Revlimid, Velcade, dexamethasone and Farydak
id
OG000
title
Arm 1 - RVD + Pan
description
Revlimid, Velcade and Dexamethasone
id
OG001
title
Arm 2 - RVD

population Description

The study was terminated prematurely and because only 6 patients were enrolled, efficacy data were not evaluated.

reporting Status

POSTED

time Frame

Month 3 up to end of study, approximately 3 years.

title

Best Overall Response Rate (ORR) and MRD Negativity After ASCT and Maintenance

type

SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice